Lucid Diagnostics (LUCD), a subsidiary of PAVmed (PAVM), has entered into a strategic partnership with VITALExam, a comprehensive medical care provider for first responders founded by CEO Marci Vitale to enhance access to Lucid’s EsoGuard Esophageal DNA Test for firefighters at risk for esophageal precancer. VITALExam is a comprehensive medical care provider dedicated to optimizing the wellness of first responders. Founded by Vitale, the company offers a range of services including cancer screenings, comprehensive physicals, and behavioral health assessments, utilizing advanced technology and evidence-based practices to provide the highest level of care to those who serve our communities.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUCD:
- Lucid announces publication on EsoGuard in peer-reviewed journal Medicina
- Lucid Diagnostics completes convertible debt refinancing
- Lucid Diagnostics’ Strategic Financial Maneuvering and Agreements
- Lucid Diagnostics submits clinical evidence for EsoGuard Esophagea DNA test
- Lucid Diagnostics Reports Q3 Revenue Growth and Strategic Expansion
Questions or Comments about the article? Write to editor@tipranks.com